Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma

We analyzed 186 patients with lymphoma who received allogeneic stem cell transplant (ASCT) with fludarabine-melphalan (FM) conditioning and different donors [25 haploidentical (HD), 98 matched unrelated (MUD), and 63 matched related (MRD)] at our institution between 09/2009-01/2018. Patients receive...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biol Blood Marrow Transplant
Autori principali: Saini, Neeraj Y., Saliba, Rima M., Rondon, Gabriela, Maadani, Farzaneh, Popat, Uday, Hosing, Chitra M., Betul, Oran, Bashir, Qaiser, Olson, Amanda, Nieto, Yago, Alousi, Amin, Kebriaei, Partow, Srour, Samer, Mehta, Rohtesh, Anderlini, Paolo, Shpall, Elizabeth J., Qazilbash, Muzaffar H., Khouri, Issa F., Fayad, Luis, Lee, Hun, Fowler, Nathan, Parmar, Simrit, Westin, Jason, Hagemeister, Fredrick, Champlin, Richard E., Ciurea, Stefan O.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265611/
https://ncbi.nlm.nih.gov/pubmed/30763728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.02.002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi